Agrochemicals company Astec Lifesciences announced Q3FY25 results Q3FY25 Financial Highlights: Consolidated total income in Q3FY25 was Rs 95.8 crore as compared to Rs 51.7 crore in Q3FY24. Consolidated EBITDA loss was Rs 3.8 crore in Q3FY25 as compared to loss of Rs 17.4 crore in Q3FY24. N B Godrej, Chairman, Astec LifeSciences, said: In Q3FY25, Astec reported sequential improvement in performance, narrowing EBITDA losses from Rs 17.7 crore in Q2 FY25 to Rs 3.8 crore in Q3FY25. This positive trend was primarily due to a sequential increase in volumes in our Contract Development and Manufacturing Organization (CDMO) business. However, this positive impact was offset by continued lower realizations in key Enterprise products.Moreover, our EBITDA losses also narrowed from Rs 17.4 crore in Q3FY24 to Rs 3.8 crore in Q3FY25. Result PDF